Fresh from Envision buy, GHO Capital acquires Canada’s Caprion Biosciences

London-based investment and advisory firm GHO Capital has acquired proteomics and immune monitoring services provider Caprion Biosciences for an undisclosed fee.

The Canadian company--a specialist lab services company which provides testing services to pharma and biotech companies for R&D--also runs its own diagnostic products targeting cancer, metabolic and infectious diseases.

The U.K.’s GHO Capital, which was only founded two years ago, gains in Caprion this expertise as well as a company with top-line growth of 22% over the past three years, and one that boasts of more than 50 pharma and biotech clients.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Mike Mortimer, partner at GHO Capital, said: “We believe that Caprion is a world-class business operating in a highly attractive, rapidly growing segment. As a well-respected service provider to the pharmaceutical industry, the management team has developed a scalable business model capable of delivering significant further growth, making this an exciting investment opportunity for our fund.

“With favourable market dynamics in immuno-oncology and proteomics, Caprion is well-positioned to expand its capabilities on a global scale.”

It’s been an acquisitive month for GHO Capital as at the beginning of July it announced its purchase of the science comms company Envision Pharma Group from its previous owner Halifax. Financial terms were here too not made public.

It may have only been around since 2014 but the firm is wasting no time and money in swiftly building up a diverse science portfolio.

Martin LeBlanc, president and CEO of Caprion, added: “We are delighted to enter into this exciting new partnership with GHO Capital.

“GHO Capital brings a unique combination and depth of relevant industry expertise, network and strategic insights that will undoubtedly help position Caprion to maintain the rapid growth trajectory we have achieved over the past seven years. We look forward to continuing to build on our leading immunology and proteomics services to further broaden our customer base and pursue our expansion both in Europe and internationally.”

- check out the release

Read more on

Suggested Articles

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.